Abstract
Recombinant DNA technology has provided the clinician with a variety of biological response modifiers (BRMs) to combine with conventional cytotoxic agents. Preclinical models have suggested interactions between particular BRMs and cytotoxic agents ranging from antagonistic to synergistic. These conflicting preclinical results reflect variations in cell lines, assays, concentrations, duration of the regimen, and sequence of exposure.1 The bases for developing combination chemotherapy regimens, such as increasing dose intensity and combining drugs that have independent antitumor activity, may not apply to those for combining BRMs and cytotoxic drugs. Thus, the rationale for adding BRMs to chemotherapy may be more complex than for combining chemotherapy drugs.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Wadler S, Schwartz EL. Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies. Cancer Res 1990;50:3473–3486.
Stolfi RL, Martin DS, Sawyer RC, Spiegelman S. Modulation of 5-fluorouracil-induced toxicity in mice with interferon or with the interferon inducer, polyinosinic-polycytidylic acid. Cancer Res 1983;43:561–566.
Grem JL, Allegra CJ, McAtee N, Balis FM, Sartor O, Goldstein LJ, Murphy RF, Sorensen JM, Hamilton JM. Phase I study of interferon alfa-2a, 5-fluorouracil and high-dose leucovorin in metastatic gastrointestinal carcinoma (abstr). Proceedings of the American Society of Clinical Oncology 1990;9:70.
Elias L, Crissman HA. Interferon effects upon the adenocarcinoma 38 and HL-60 cell lines: anti-proliferative responses and synergistic interactions with halogenated pyrimidine antimetabolites. Biochem Biophys Res Comm 1989;163: 867–874.
Mitchell MS, Kempf RA, Harel W, Shau H, Boswell WD, Lind S, Bradley EC. Effectiveness and tolerability of low-dose intravenous interleukin-2 in disseminated melanoma. J Clin Oncol 1988;6:409–424.
Chu E, Zinn S, Boarman D, Allegra CJ. Interaction of gamma interferon and fluorouracil in the H630 human colon carcinoma cell line. Cancer Res 1990;50:5834–5840.
Matheson DS, Green BJ, Friedman SJ, Hoar DI. Studies on the mechanism of activation of human natural killer function by interferon and inhibitors of thymidylate synthesis. Cell Immunol 1988;111:118–125.
Einhorn LH. Improvements in fluorouracil chemotherapy? J Clin Oncol 1989;7:1377–1379.
Poon MA, O’Connell MJ, Moertel CG, Wieand HS, Cullinan SA, Everson LK, Krook JE, Mailliard JA, Laurie JA, Tschetter LK, Wiesenfeld M. Biochemical modulation of fluorouracil: evidence of significant improvements of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989;7:1407–1418.
Erlichman C, Fine S, Wong A, Elhakim T. A randomized trial offluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 1988;6:469–475.
Gutterman JU, Fein S, Quesada J, Horning SJ, Levine JF, Alexanian R, Bernhardt L, Kramer M, Spiegel H, Colburn W, Trown P,. Merigan T, Dziewanowski Z. Recombinant leukocyte A interferon: pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients. Ann Intern Med 1982;96:549–556.
Wadler S, Schwartz EL, Goldman M, Lyver A, Rader M, Zimmerman M, Itri L, Weinberg V, Wiernik PH. Fluorouracil and recombinant alfa2a-interferon: an active regimen against advanced colorectal carcinoma. J Clin Oncol 1989;7:1769–1775.
Wadler S, Wiernik PH. Clinical update on the role of fluorouracil and recombinant interferon alfa-2a in the treatment of colorectal carcinoma. Semin Oncol 1990;17:16–21.
Pazdur R, Ajani JA, Patt YZ, Winn R, Jackson D, Shepard B, DuBrow R, Campos L, Quaraishi M, Faintuch J, Abbruzzese J, Gutterman J, Levin B. Phase II study of fluorouracil and recombinant interferon alfa-2a in previously untreated advanced colorectal carcinoma. J Clin Oncol 1990;8:2027–2031.
Kemeny N, Younes A, Seiter K, Kelsen D, Sammarco P, Adams L, Derby S, Murray P, Houston C. Interferon alpha-2a and 5-fluorouracil for.advanced colorectal carcinoma: assessment of activity and toxicity. Cancer 1990;66:2470–2475.
Wadler S, Lembersky B, Kirkwood J, Atkins M, Petrelli N. Phase II trial of fluorouracil and recombinant alfa-2a interferon in patients with advanced colorectal cancer: an Easternn Cooperative Oncology Group (ECOG) Study (abstr). Proceedings of the American Society of Clinical Oncology 1991;10:136.
Wadler S, Goldman M, Lyver A, Wiernick PH. Phase I trial of 5fluorouracil and recombinant alfa-2a interferon in patients with advanced colorectal carcinoma. Cancer Res 1990;50:2056–2059.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1992 Springer Science+Business Media New York
About this chapter
Cite this chapter
Pazdur, R. (1992). Combination of Fluorouracil and Interferon: Mechanisms of Interaction and Clinical Studies. In: Goldstein, A.L., Garaci, E. (eds) Combination Therapies. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3340-5_9
Download citation
DOI: https://doi.org/10.1007/978-1-4615-3340-5_9
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6472-6
Online ISBN: 978-1-4615-3340-5
eBook Packages: Springer Book Archive